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A B S T R A C T
Meningococcal invasive disease is a life-threaten-
ing infection that affects mostly children and
adolescents. The present study was performed
during 2003–2005 to compare the phenotypic
characteristics of meningococcal isolates from
these two main groups at risk with those of
isolates from other age groups to assess whether
strategies for treatment and prevention imple-
mented elsewhere can also be applied in Italy.
The results showed that serogroup C meningo-
cocci were predominant, and that a dramatic
increase in the circulation of strains with de-
creased susceptibility to penicillin was associated
mainly with a prevalent phenotype C:2b:P1.5,2,
which belongs to the hyper-virulent ST8 ⁄A4
cluster.
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Children in the first few years of life and adoles-
cents are the two age groups most at risk of
developing invasive meningococcal disease. De-
spite the availability of a targeted therapy, the
disease remains life-threatening, and many efforts
have been made in recent years to design safe
immunogenic vaccines. Currently, polysaccharide
and conjugate vaccines can prevent cases caused
by Neiserria meningitidis serogroups A, C, Y and
W135, and serogroup C only, respectively [1,2]. In
addition, the newer outer-membrane vesicle
(OMV) vaccines, which contain the meningococ-
cal outer-membrane proteins (PorA) of class 1 that
are normally used for strain subtyping [3], seem
to be able to overcome the disadvantages of
immunogenicity and cross-reactivity with host
tissue that occur with the meningococcal B poly-
saccharide [4]. The main constraint in the devel-
opment of OMV vaccines is the great diversity of
sero-subtypes circulating in different geograph-
ical areas, which would require ad-hoc vaccine
production tailored to each specific situation [5,6].
Meningococci with decreased susceptibility to
penicillin (PenI) have been described since the
mid-1980s [7], and their frequency is increasing
constantly throughout the world. Although fully-
resistant strains have not yet been isolated in
Italy, the situation requires constant monitoring.
The aim of the present work was to assess the
meningococcal phenotypes circulating during
2003–2005 in Italy in the two groups most at risk,
i.e., children aged £4 years and adolescents aged
15–19 years, since different opportunities are
available for prophylaxis and it is imperative
for national public health laboratories to have
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up-to-date data concerning the phenotypic
characteristics of meningococci isolated from
cases of invasive disease. National surveillance
of meningococcal invasive disease is ongoing in
Italy, and the Istituto Superiore di Sanita`, Rome
acts as a national reference laboratory, with data
being forwarded to the EU Invasive Bacterial
Infection Surveillance Network (EU-IBIS, http://
www.euibis.org) every 6 months.
During 2003–2005, 923 cases of invasive men-
ingococcal disease were notified to the national
surveillance network. Of these, 670 (72%) were
confirmed by culture; the National Reference
Laboratory received 433 viable isolates, mainly
from cerebrospinal fluid or blood of patients. The
isolates were subcultured on Thayer Martin agar,
and the serogroup was then identified by slide
agglutination with commercial antisera (Oxoid,
Milan, Italy). Serotyping and subtyping were
performed by whole-cell enzyme-linked immuno-
assay with monoclonal antibodies (NIBSC, Potters
Bar, UK) [8]. MICs of penicillin, rifampicin,
ceftriaxone and sulphadiazine were determined
by Etest (AB Biodisk, Solna, Sweden) on Mueller–
Hinton agar (Oxoid), supplemented with lysed
horse blood 5% v ⁄ v, incubated in CO2 5% at 35C
for 24 h. Breakpoint criteria were those recom-
mended by the CLSI [9].
Of the 433 viable isolates, 227 were serogroup
C, 188 were serogroup B, eight were serogroup Y,
seven were serogroup W135, and three were non-
serogroupable. Serotype and subtype could be
determined for 76% of the isolates, but 38 isolates
were not serotypeable, 50 were not subtypeable,
and 15 were neither serotypeable nor subtype-
able. Serogroup C was found to have replaced
serogroup B as the predominant serogroup since
2004. The most common phenotypes during the 3-
year period were C:2b:P1.5,2 (22.3%), C:2b:P1.5
(7.8%) and B:15:P1.4 (7%) (Table 1).
The prevalent phenotypes of isolates from
children and adolescents reflected the trend des-
cribed above, with 117 serogroup C isolates
representing 61% of all meningococci isolated
from these two age groups. Overall, the
C:2b:P1.5,2 phenotype was predominant, account-
ing for 50% of isolates in children and 41% in
adolescents. Serogroup B accounted for just over
one-third of meningococci detected in these two
age groups, but no particular phenotype was
predominant, with B:15:P1.4 and B:4:P1.3,6 each
representing c. 10% of isolates.
Examining the changes in the most prevalent
phenotypes within each serogroup on an annual
basis, phenotype C:2b:P1.5 disappeared in 2005,
although it accounted for 46.3% of isolates during
2003. The C:2b:P1.5,2 phenotype appeared for the
first time in 2003, and then increased to account
for 50% and 59.3% of isolates in 2004 and 2005,
respectively. Selected isolates from these two
phenotypes that were examined by multilocus
sequence typing [10] were all assigned to the
ST8 ⁄A4 cluster. A wide variety of sero ⁄ subtypes
was observed among serogroup B isolates, but
some minor changes occurred. Thus, B:15:P.1.4
accounted for 10.1% of isolates in 2005, compared
with 18.6% and 20% of isolates in 2003 and 2004,
respectively, and B:NT:P1.9 accounted for 1.4% of
isolates in 2003, compared with 7.2% of isolates in
2005. The relative proportions of other pheno-
types, e.g., B:14:P1.13, B:15:P1.7,16 and B:4:P1.4,
did not vary significantly, accounting for 4–7% of
isolates. Non-serotypeable isolates were more
frequent among serogroup B isolates (17.4% in
Table 1. Serogroup B and sero-
group C meningococci circulating
in Italy during 2003–2005
Serogroup B Serogroup C
Phenotype 2003 2004 2005 Phenotype 2003 2004 2005
B:14:P1.13 5 2 4 C:2a:P1.5 10 4 9
B:15:P1.16 5 2 2 C:2b:nst 5 12 8
B:15:P1.4 13 10 7 C:2b:P1.2 0 4 5
B:15:P1.7,16 4 2 4 C:2b:P1.5 25 9 0
B:4:P1.13 2 7 4 C:2b:P1.5,2 2 41 54
B:4:P1.15 2 2 4 C:nt:nst 4 1 1
B:4:P1.3,6 2 2 5
B:4:P1.4 4 2 3
B:nt:nst 3 2 3
B:nt:P1.5 4 0 0
B:nt:P1.9 1 4 5
Other
phenotypes
23 15 29 Other
phenotypes
8 11 14
Total 68 50 70 54 82 91
nt, not typeable; nst, not subtypeable.
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2005) than among serogroup C isolates (6.6%),
while non-subtypeable isolates were distributed
equally (13%) between the two serogroups.
Table 2 shows MIC50 and MIC90 values of
penicillin, rifampicin, sulphadiazine and ceftriax-
one. Decreased susceptibility to penicillin in-
creased among serogroup C isolates during the
3-year period, from 50.9% to 87.4%. This was
associated mainly with C:2b:P1.5,2 isolates; since
the first appearance of this phenotype in 2003,
>95% of isolates have shown decreased suscep-
tibility to penicillin (MICs 0.094–0.380 mg ⁄L).
Since this phenotype was predominant in all age
groups, no great difference was observed in terms
of distribution of serogroup C PenI isolates
among the different age groups. In contrast, a
greater proportion of serogroup B isolates with
decreased susceptibility to penicillin was isolated
from children and adolescents than from other
age groups. Interestingly, resistance to rifampicin
was rare [11] (only one isolate in 2004 from a
child aged 4 years), despite its long use for
prophylaxis of close contacts, and sometimes for
entire small communities, e.g., schools, colleges
and gymnasiums.
In conclusion, serogroup C meningococci were
predominant in the two age groups most at risk of
developing disease during 2003–2005 in Italy. The
dramatic increase in the circulation of meningo-
cocci with decreased susceptibility to penicillin
requires careful monitoring, and this issue must
be considered when determining vaccination
strategies. Serogroup B isolates showed a large
range of different phenotypes and therefore the
use of OMV vaccines does not seem to be feasible
at the present time. Indeed, none of the subtypes
included in the hexavalent OMV vaccine that is
currently being evaluated in the UK (i.e., P1.7,16;
P1.5,2; P1.19,15; P1.7; P1.5; and P1.12,13) [12] was
significantly represented among group B isolates
circulating in Italy.
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Table 2. Antimicrobial suceptibility data for 433 meningococci circulating in Italy during 2003–2005
Antibiotic
2003 2004 2005
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Penicillin
Serogroup B isolates 0.047 0.064 0.012–0.380 0.032 0.094 0.012–0.250 0.064 0.125 0.012–0.250
Serogroup C isolates 0.094 0.190 0.012–0.380 0.125 0.250 0.023–0.380 0.125 0.190 0.023–0.180
Rifampicin 0.016 0.064 <0.002–0.250 0.016 0.064 <0.002–256 to >256 0.016 0.032 <0.002–0.380
Sulphadiazine >256 >256 0.064 to >256 >256 >256 0.064–256 >256 >256 0.125 to >256
Ceftriaxone <0.002 <0.002 <0.002–0.023 <0.002 <0.002 <0.002–0.004 <0.002 <0.002 <0.002–0.094
MIC values are expressed in mg ⁄L.
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A B S T R A C T
The prevalence of macrolide–lincosamide–strep-
togramin (MLS) resistance phenotypes was
determined among erythromycin-resistant
Staphylococcus epidermidis isolates collected at the
Bone Marrow Transplant Centre, Tunisia during
2002. The erm(A), erm(B), erm(C), msrA, mefA and
icaA genes were detected by PCR. The vga, vgb
and vat genes were amplified from pristinamycin-
resistant isolates. The icaA gene was detected in
76.5% of 34 isolates examined in detail. The
erm(C) (53%) and erm(A) (32%) genes predomin-
ated because of clonal dissemination, followed by
msrA (15%). Gene distribution was related to the
methicillin resistance pattern. The vga gene was
present in combination with erm(A) in three
isolates.
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Coagulase-negative staphylococci are the bacteria
isolated most frequently from the blood cultures
of febrile neutropenic patients, particularly in
association with the use of intravenous catheters
[1]. Resistance to macrolides is conferred either by
methylases, encoded by erm genes that modify the
ribosomal target of macrolides [2], or by efflux
pumps, encoded by the msrA gene. Ribosomal
methylation results in cross-resistance to macro-
lide, lincosamide and streptogramin B antibiotics
(MLSB phenotype) [3], and can be expressed
either constitutively (cMLSB) or inducibly (iMLSB)
[4]. Macrolide efflux is characterised by resistance
to 14- and 15-membered-ring macrolides (M
phenotype) [5]. The aims of the present study
were to determine the incidence and patterns of
antimicrobial resistance among Staphylococcus epi-
dermidis isolates from Tunisia, to correlate eryth-
romycin and pristinamycin resistance with the
presence of the MLS resistance genes erm(A),
erm(B), erm(C), msrA, mefA, vga, vgb and vat, to
search for the presence of the icaA gene in these
isolates, and to assess their molecular epidemiol-
ogy.
During 2002, 55 S. epidermidis isolates from
blood cultures and 22 isolates from the intravas-
cular catheters of 34 patients with haematological
cancer at the Centre National de Greffe de Moelle
Osseuse, Tunis, Tunisia were analysed. Isolates
were identified using conventional methods and
the ID-32 Staph system (bioMe´rieux, Marcy l’Eto-
ile, France). Susceptibility to antibiotics was tested
using the agar diffusion technique. MICs were
determined using the agar dilution method
according to French guidelines [6]. Resistance
phenotypes of erythromycin-resistant isolates
were determined using erythromycin, spiramy-
cin, clindamycin, lincomycin and pristinamycin
disks. Thirty-four erythromycin-resistant isolates
were chosen randomly for PCR amplification of
macrolide resistance genes [7–9] using the prim-
ers shown in Table 1. A multiplex PCR assay was
used to amplify erm(A), erm(C) and msrA [8]; a
duplex PCR was used to amplify erm(B) and mefA
[10]; and individual PCRs were used to detect
vga, vgb, vat [11] and icaA [9]. Pulsed-field gel
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